Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 3/20 | 0.60 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.60 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | BCR | P11274 | 1/20 | 0.56 |
| ▸ | SRC | P12931 | 1/20 | 0.56 |
| ▸ | PRKCA | P17252 | 1/20 | 0.56 |
| ▸ | PRKACA | P17612 | 1/20 | 0.56 |
| ▸ | PRKACG | P22612 | 1/20 | 0.56 |
| ▸ | PRKACB | P22694 | 1/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 5/20 | 0.56 |
| ▸ | CDK1 | P06493 | 5/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 5/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 5/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 5/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509559 | 0.85 | FLT3 (0.71) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL4510383 | 0.82 | FLT3 (0.64) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL31588329 | 0.81 | CCNB2 (0.76) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL144954 | 0.81 | CCNB2 (0.76) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL4518219 | 0.81 | RET (0.79) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL4517500 | 0.79 | FLT3 (0.60) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL7467183 | 0.79 | FLT3 (0.60) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL140969 | 0.79 | CCNB2 (0.64) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL20691186 | 0.76 | EIF2AK2 (0.67) | FLT3MKNK1MKNK2EGFRABL1 | |
| SCHEMBL13051125 | 0.76 | DYRK1B (0.61) | FLT3MKNK1MKNK2CCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | claimed |
| CN-101111490-A | 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivatives and their therapeutic use | CYCLACEL LTD (GB) | 2008-01-23 | — | — | CN | claimed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | claimed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | claimed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | CYCLACEL LIMITED (GB) | 2009-12-24 | — | — | US | disclosed |
| CN-101111490-A | 4- (1H-indol-3-yl) -pyrimidin-2-ylamine derivatives and their therapeutic use | CYCLACEL LTD (GB) | 2008-01-23 | — | — | CN | disclosed |
| EP-1836194-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006075152-A1 | 4- (1H-INDOL-3-YL) -PYRIMIDIN-2-YLAMINE DERIVATES AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318446-A1 | 4-(1H-Indol-3-yl)-Pyrimidin-2-Ylamine Derivatives and Their Use in Therapy | ABL1, CDK2, JAK2 | FLT3 91/4885MKNK1 109/4885MKNK2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.